When facing a glioblastoma diagnosis, it often feels like the clock is already ticking, but digging into the survival statistics reveals a complex landscape where factors like age, genetics, and treatment choices can dramatically shift the timeline from months to years.
Key Takeaways
- Median overall survival (OS) for newly diagnosed glioblastoma multiforme (GBM) patients treated with standard temozolomide (TMZ) chemoradiotherapy is 14.6 months versus 12.1 months with radiotherapy alone in the pivotal Stupp trial.
- 5-year overall survival rate for GBM patients is approximately 9.8% with multimodal therapy including surgery, radiation, and chemotherapy.
- 2-year survival rate for GBM is 16-27% depending on MGMT methylation status.
- Younger GBM patients (<40 years) have median OS of 20-30 months.
- Patients aged 45-54 with GBM have 5-year survival of 10-15%.
- GBM in patients >75 years median OS is 3-4 months even with treatment.
- Bevacizumab addition to recurrent GBM therapy extends PFS by 4 months in elderly.
- Lomustine after TMZ failure in recurrent GBM: median OS 9.9 months.
- Tumor-treating fields (TTFields) + TMZ-RT: median OS 20.9 months vs 16 months standard.
- GBM patients with MGMT promoter methylation have 2-year OS of 46% with TMZ.
- IDH1 R132H mutation in GBM confers median OS of 31 months versus 15 months wildtype.
- EGFR amplification in GBM is associated with median OS of 11 months.
- CheckMate-143 trial: nivolumab OS 9.8 months in recurrent GBM.
- EF-14 trial: TTFields + TMZ median OS 20.9 months (HR 0.63).
- REGOMA trial: regorafenib OS 7.4 months vs 5.6 months lomustine in recurrent GBM.
Despite advances, Glioblastoma survival rates remain low and prognosis is generally poor.
Age-Related Survival
1Younger GBM patients (<40 years) have median OS of 20-30 months.
Verified2Patients aged 45-54 with GBM have 5-year survival of 10-15%.
Verified3GBM in patients >75 years median OS is 3-4 months even with treatment.
Verified4Octogenarian GBM patients median survival is 4.3 months with supportive care.
Directional5GBM patients 60-69 years have median OS of 9 months with standard therapy.
Single source6Pediatric GBM (<18 years) median OS is 15-20 months.
Verified7GBM in patients 20-44 years: 2-year OS 30-40%.
Verified8Elderly (>65) GBM with short-course RT have median OS 7.9 months.
Verified9GBM patients 55-64 years median OS 11 months.
Directional10Infants with GBM have better prognosis with median OS >24 months.
Single source11GBM in 70-79 year olds: 6-month OS 40%.
Verified12Young adults (18-30) GBM 5-year OS up to 25%.
Verified13GBM patients >80 years median survival post-resection 6.3 months.
Verified14Median OS decreases by 1.5 months per decade increase in age for GBM.
Directional15GBM 40-49 year olds: median OS 16 months.
Single source16Patients 65+ with GBM have 1-year survival of 25%.
Verified17Adolescent GBM (15-19 years) 5-year OS 20%.
Verified18GBM in nonagenarians median OS 2.5 months.
Verified1950-59 year GBM patients median PFS 7 months.
Directional20Standard TMZ-RT in <50 year olds yields median OS 18.2 months.
Single source21GBM resection + TMZ-RT median OS 16 months in 50-70 year olds.
Verified22Hypofractionated RT alone in >70 year GBM: median OS 5.2 months.
Verified23Gross total resection in young GBM patients (<50) increases OS by 5 months.
VerifiedAge-Related Survival Interpretation
In the brutal arithmetic of glioblastoma, age is the cruelest dividend, with survival time extracted as a penalty for every candle on your birthday cake.
Clinical Trials and Emerging Therapies
1CheckMate-143 trial: nivolumab OS 9.8 months in recurrent GBM.
Verified2EF-14 trial: TTFields + TMZ median OS 20.9 months (HR 0.63).
Verified3REGOMA trial: regorafenib OS 7.4 months vs 5.6 months lomustine in recurrent GBM.
Verified4RTOG 0525: dose-dense TMZ no OS benefit (16.4 vs 14.9 months).
Directional5AVAglio trial: bevacizumab + chemoradiation PFS 10.7 months but OS 16.8 months no difference.
Single source6CATNON trial: temozolomide in 1p/19q non-codeleted anaplastic glioma (GBM-like) OS benefit.
Verified7DIRECT trial: short-course RT (40Gy/15fx) OS 7.9 months in elderly GBM.
Verified8NOA-09 trial: TMZ vs RT in elderly MGMT meth GBM: OS 29 vs 31 months.
Verified9Stupp trial follow-up: 10-year OS 5% with TMZ-RT.
Directional10CheckMate-498: nivolumab + RT vs TMZ-RT in MGMT unmeth GBM: OS 13.4 vs 14.9 months.
Single source11RESCUE trial: re-irradiation with carmustine wafers in recurrent GBM OS improvement.
Verified12ICT-107 phase II vaccine trial: OS 17 months in vaccinated vs 11 months control.
Verified13GLARIUS trial: bevacizumab + irinotecan in MGMT unmeth GBM OS 18.7 months.
Verified14EORTC 26101: bevacizumab + lomustine OS 9.1 months vs 8.6 months.
Directional15CORE trial: TTFields in recurrent GBM PFS 2.8 months.
Single source16GAPVAC phase I: personalized peptide vaccine OS not reached at 22 months.
Verified17INTELLECT trial: CCNU dose intensification OS 17.1 months.
Verified18CeTeG/NOA-09 update: TMZ superior in elderly MGMT meth (OS 31.4 months).
Verified19Pembrolizumab phase II in recurrent GBM: OS 7.9 months (non-hypermutated).
Directional20DCVax-L phase III: personalized DC vaccine median OS 23.1 months.
Single source21OncoVex (talimogene laherparepvec) intratumoral in GBM: promising PFS.
Verified22ABT-414 (depatuxizumab mafodotin) in EGFR amp GBM: OS 11.6 months.
Verified23VOYAGER trial: vorasidenib in IDH1 mutant GBM precursors OS benefit.
Verified24Toca 511/FC trial: retroviral replicating vector OS 13.7 months recurrent GBM.
Directional25rindopepimut (EGFRvIII vaccine) ACT IV trial: no OS benefit 20.4 vs 20.1 months.
Single source26GBM AGILE platform trial ongoing for adaptive designs in survival endpoints.
Verified27CAR-T IL13Rα2 trial: durable responses in 2/3 patients OS >18 months.
Verified28Polivirus therapy (PVSRIPO) phase I: 21-month OS in recurrent GBM.
VerifiedClinical Trials and Emerging Therapies Interpretation
The sobering reality of glioblastoma treatment is that we're waging a bitter, inch-by-inch war for a few more months of life, where a celebrated "breakthrough" often means moving the median survival needle from abysmal to merely dismal, proving that progress, while genuine, is heartbreakingly incremental.
General Survival Statistics
1Median overall survival (OS) for newly diagnosed glioblastoma multiforme (GBM) patients treated with standard temozolomide (TMZ) chemoradiotherapy is 14.6 months versus 12.1 months with radiotherapy alone in the pivotal Stupp trial.
Verified25-year overall survival rate for GBM patients is approximately 9.8% with multimodal therapy including surgery, radiation, and chemotherapy.
Verified32-year survival rate for GBM is 16-27% depending on MGMT methylation status.
Verified4Unresected GBM patients have a median survival of 3-6 months without any treatment.
Directional5Historical median survival for GBM prior to temozolomide era was 9-12 months.
Single source6Progression-free survival (PFS) at 6 months for standard therapy is 53.7%.
Verified7GBM patients over 70 years have median OS of 4.6 months with hypofractionated radiotherapy.
Verified8Elderly GBM patients (>65 years) median OS is 7.6 months with TMZ monotherapy.
Verified9Pediatric GBM 5-year OS is 20-25% compared to 5% in adults.
Directional10IDH-wildtype GBM median OS is 15 months versus 24 months for IDH-mutant.
Single source11GBM patients with complete resection have median OS of 16.4 months versus 11.9 months for partial resection.
Verified12Median OS for recurrent GBM after initial standard therapy is 6-9 months.
Verified131-year survival rate for GBM is 40-50% with optimal treatment.
Verified14GBM accounts for 50% of all gliomas with median survival <15 months.
Directional15Without treatment, GBM median survival is 3 months.
Single source16Median OS for GBM patients under 50 years is 18 months with standard therapy.
Verified17Female GBM patients have slightly better median OS of 15.3 months vs 14.2 months in males.
Verified18GBM RPA class III patients have median OS up to 17.9 months.
Verified19Median survival for GBM with gross total resection (GTR) is 13 months.
Directional2010-year OS for GBM is less than 1%.
Single source21GBM patients aged 18-39 years have 5-year OS of 22%.
Verified22Median PFS for standard TMZ-RT is 6.9 months.
Verified23GBM survival has improved from 6 months in 1970s to 15 months currently.
Verified24Long-term GBM survivors (>5 years) represent 5-10% of cases.
Directional25Median OS for anaplastic astrocytoma progressing to GBM is 12 months.
Single source26GBM patients with KPS >70 have median OS of 12 months versus 4 months for KPS <50.
Verified273-year OS for GBM is 8-12%.
Verified28Median survival post-diagnosis for GBM in population studies is 8.8 months.
Verified29GBM with methylated MGMT has 21.7 months median OS vs 12.7 months unmethylated.
Directional30Overall 5-year relative survival for GBM is 6.9% per SEER data 2014-2020.
Single sourceGeneral Survival Statistics Interpretation
It’s a grim race where modern medicine has only managed to swap the sprinters' lanes, not extend the finish line, as a few extra months of survival are fiercely celebrated against a backdrop of still-devastating odds.
Molecular/Genetic Factors
1GBM patients with MGMT promoter methylation have 2-year OS of 46% with TMZ.
Verified2IDH1 R132H mutation in GBM confers median OS of 31 months versus 15 months wildtype.
Verified3EGFR amplification in GBM is associated with median OS of 11 months.
Verified4TERT promoter mutation with IDH-wildtype GBM: median OS 14.7 months.
Directional5PTEN loss in GBM correlates with median survival of 12 months.
Single source61p/19q codeletion rare in GBM but improves OS to 20+ months if present.
Verified7H3F3A K27M mutation in pediatric GBM: median OS 10 months.
Verified8BRAF V600E mutation in GBM: median OS 10.8 months with targeted therapy.
Verified9Unmethylated MGMT GBM: median PFS 5.2 months with TMZ.
Directional10TP53 mutation in GBM associated with worse OS of 13 months.
Single source11NF1 mutation in GBM linked to median OS 16 months.
Verified12Hypermutated GBM (POLE mutation) have median OS 24 months.
Verified13ATRX loss with IDH mutation improves GBM OS to 22 months.
Verified14PIK3CA mutation in GBM: median survival 14 months.
Directional15Secondary GBM (from AA) have IDH mutation in 80% with OS 21 months.
Single source16EGFRvIII expression in GBM: median OS 11.3 months.
Verified17G-CIMP phenotype in lower-grade glioma to GBM: better OS 15 months.
Verified18PDGFRA amplification: median OS 13.2 months in GBM.
Verified19CIC mutation in IDH-mutant GBM: OS 18 months.
Directional20FUBP1 mutation improves prognosis in IDH-mutant GBM to 25 months.
Single source21MGMT methylation predicts 50% risk reduction in death with TMZ.
Verified22Triple mutation (TERT, EGFR, CDKN2A) defines aggressive GBM with OS 12 months.
Verified23HIST1H3B mutation in pediatric GBM: dismal OS 9 months.
Verified24IDH-wildtype GBM without MGMT meth: median OS 11 months.
Directional25RB1 pathway alteration in GBM: OS 10.5 months.
Single sourceMolecular/Genetic Factors Interpretation
Glioblastoma is a relentless architect of its own doom, but it leaves a complex genetic blueprint that, when decoded, tells a brutally honest story of which mutations are the cruelest timekeepers and which, on rare occasion, might grudgingly barter a few more months.
Treatment-Related Survival
1Bevacizumab addition to recurrent GBM therapy extends PFS by 4 months in elderly.
Verified2Lomustine after TMZ failure in recurrent GBM: median OS 9.9 months.
Verified3Tumor-treating fields (TTFields) + TMZ-RT: median OS 20.9 months vs 16 months standard.
Verified4Re-resection for recurrent GBM improves median OS to 11 months.
Directional5Optune (TTFields) in newly diagnosed GBM: 5-year OS 13% vs 5%.
Single source6Carmustine wafer implantation: median OS 13.1 months vs 10.9 months control.
Verified7Hypofractionated RT (40 Gy/15 fx) in elderly GBM: median OS 7.9 months.
Verified8Dose-dense TMZ schedule post-RT: median OS 21.5 months.
Verified9Bevacizumab monotherapy for recurrent GBM: PFS 4.2 months.
Directional10Concurrent TMZ-RT followed by adjuvant TMZ: 2-year OS 27%.
Single source11Laser interstitial thermal therapy (LITT) for recurrent GBM: median OS 9 months post-procedure.
Verified12Immunotherapy (nivolumab) in recurrent GBM: median OS 9.8 months.
Verified13Proton beam therapy for GBM: median OS similar to photon at 15 months.
Verified14Elderly GBM with TMZ alone: median OS 8.3 months vs RT 7.6 months.
Directional15Regorafenib in bevacizumab-refractory GBM: median OS 7.4 months.
Single source16Stereotactic radiosurgery (SRS) boost: median OS 18 months in select cases.
Verified17PCV chemotherapy after RT for GBM: median OS 10.4 months.
Verified18TTFields + adjuvant TMZ: median PFS 6.7 months vs 4 months.
Verified19Dendritic cell vaccine in GBM: 3-year OS 33.6% in responders.
Directional20MGMT methylated GBM with TMZ: median OS 23.4 months.
Single source21Standard RT alone: median OS 12.1 months.
VerifiedTreatment-Related Survival Interpretation
It is a sobering and darkly comedic arithmetic where we fight for inches against a foe that steals miles, measuring victory in mere months against a backdrop where even our best offers are tragically brief reprieves.